Online inquiry

IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5301MR)

This product GTTS-WQ5301MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ALCAM gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001243280.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 214
UniProt ID Q13740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5301MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3786MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ4015MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BGB-A317
GTTS-WQ2197MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ11080MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ6145MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CP-675
GTTS-WQ6955MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ5361MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ4556MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-936564
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW